OUR APPROACH The company's Multi-Biomarker Panel approach, combined with its technological and clinical expertise, promises to generate molecular blood tests as well as tissue-based diagnostic (IHC) tests with high specificity and sensitivity. Cancer has attracted a great deal of interest as the area of choice for the development of biomarker-based diagnostics. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis Novel Biomarker – Our goal is to in-license individual, validated tumor markers with proven clinical efficacy and to generate multiple biomarker panels. Superior clinical performance – The integration of multiple, high value biomarkers promises to provide high sensitivity and specificity in both early and recurring disease as compared to individual markers. Blood or Tissue based kits – The use of a simple, non-invasive tests offers an ideal solution for widespread, and repeat, long-term measurements.